Ex Vivo Gene Editing of Human Hematopoietic Stem Cells for the Treatment of X-Linked Hyper-IgM Syndrome
Grant Award Details
Grant Type:
Grant Number:
TRAN1-11536
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$4,896,628
Status:
Active
Grant Application Details
Application Title:
Ex Vivo Gene Editing of Human Hematopoietic Stem Cells for the Treatment of X-Linked Hyper-IgM Syndrome
Public Abstract:
Translational Candidate
Human hematopoietic stem cells that have been gene-corrected at the CD40L gene to treat patients with X-Linked Hyper-IgM Syndrome
Area of Impact
These studies will bring stem cell gene therapy for XHIM closer to the clinic especially those without an HLA match or infections too severe for HSCT.
Mechanism of Action
The CRISPR/Cas9 platform allows site-specific integration of a corrective copy of the CD40L gene at its normal location, maintaining expression of the corrective DNA under control of natural regulatory elements. Transplantation of gene-corrected hematopoietic stem cells, which are self-renewing and long-lived, produces all blood lineages, including T lymphocytes with restored CD40L expression than can stimulate B cells to produce class-switched immunoglobulin.
Unmet Medical Need
There is no curative treatment for XHIM patients without a bone marrow match or with severe infections. Gene corrected HSC can cure XHIM and provides a therapeutic option for these patients. This proposal will advance the field of stem cell gene therapy and treatment of primary immunodeficiencies.
Project Objective
Pre-IND meeting
Major Proposed Activities
Human hematopoietic stem cells that have been gene-corrected at the CD40L gene to treat patients with X-Linked Hyper-IgM Syndrome
Area of Impact
These studies will bring stem cell gene therapy for XHIM closer to the clinic especially those without an HLA match or infections too severe for HSCT.
Mechanism of Action
The CRISPR/Cas9 platform allows site-specific integration of a corrective copy of the CD40L gene at its normal location, maintaining expression of the corrective DNA under control of natural regulatory elements. Transplantation of gene-corrected hematopoietic stem cells, which are self-renewing and long-lived, produces all blood lineages, including T lymphocytes with restored CD40L expression than can stimulate B cells to produce class-switched immunoglobulin.
Unmet Medical Need
There is no curative treatment for XHIM patients without a bone marrow match or with severe infections. Gene corrected HSC can cure XHIM and provides a therapeutic option for these patients. This proposal will advance the field of stem cell gene therapy and treatment of primary immunodeficiencies.
Project Objective
Pre-IND meeting
Major Proposed Activities
- Characterize clinical grade critical reagents in healthy and XHIM hematopoietic stem cells. Perform clinical scale run and pilot toxicology study.
- Assess off-target insertions and deletions caused by CRISPR/Cas9 in additional cell lines and in primary hematopoietic stem cells.
- Prepare clinical protocol, investigator's brochure, consent forms, and Pre-IND package. Complete Pre-IND meeting with the FDA.
Statement of Benefit to California:
Safe, definitive therapies for XHIM represent an unmet medical need. Allogeneic stem cell transplant is frequently complicated by graft-versus-host disease and worsening of pre-existing infections. Successful demonstration that stem cell gene therapy can safely and effectively cure XHIM will shift the paradigm by which patients will be treated, led by California’s position as a leader in the field of gene therapy. This will result in improved patient care in the state and around the world.